Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Tuberous sclerosis (TSC) is a genetic disorder caused by mutations in TSC1 or TSC2 genes.
• TSC is associated with autism spectrum disorders (ASD) in 20-60% of cases.
• Altered TSC/mTOR signaling is a common feature in a subset of ASD.

Purpose of the Study:

• To investigate the therapeutic potential of restoring molecular defects in the TSC/mTOR pathway in the context of ASD.
• To determine if interventions in adult animal models can ameliorate neurological dysfunction.

Main Methods:

• Utilized animal models of TSC.
• Focused on restoring the underlying molecular defect.
• Administered treatment in adult animals.

Main Results:

• Restoration of the molecular defect improved neurological dysfunction in multiple animal models.
• Treatment efficacy was observed even when initiated in adult animals.
• This suggests that pathological processes in the mature brain contribute significantly to the neurological phenotype.

Conclusions:

• Therapeutic intervention windows for ASD may be broader than previously assumed.
• Targeting TSC/mTOR signaling holds promise for ASD treatment.
• Further research into late-stage interventions for ASD is warranted.